Reports Q2 revenue $22M, consensus $24.07M. The company said, "Our Software as a Service business continued to generate solid year over year revenue growth. Looking ahead, we are optimistic about several significant opportunities in our SaaS and software sales pipelines and the potential of our recently launched products."
CytRx highlighted clinical data from partner NantCell's poster presentation on June 2, 2018 at the American Society of Clinical Oncology Annual Meeting, in Chicago. The data demonstrates the lack of cardiac toxicity associated with treatment with aldoxorubicin. These results were obtained from two clinical trials of aldoxorubicin, a rationally-engineered cytotoxic which employs a linker bound to albumin to deliver doxorubicin directly into the tumor. Results from the study showed that no patient developed any sign or symptom of clinical congestive heart failure. CytRx out-licensed global development, manufacturing, and commercialization rights for aldoxorubicin to NantCell, a private subsidiary of NantWorks, LLC, in July 2017.
NantHealth unveiled Liquid GPS for blood-based tumor profiling and quantitative monitoring at the American Society of Clinical Oncology 2018 Annual Meeting. Liquid GPS is a blood-based molecular test that provides oncologists with a tool to continuously monitor and profile tumors, an approach that is less invasive than a traditional biopsy. Liquid GPS expands upon NantHealth's molecular analysis portfolio of products, which includes the tissue-based GPS Cancer solution. Liquid GPS offers sophisticated analysis tools - looking beyond cfDNA to cfRNA. This technology allows more comprehensive profiling and trending of biomarkers that can't be assessed by cfDNA alone. As a result, Liquid GPS offers a rich portrait of a patient's condition and offers more therapeutic targets, such as chemotherapy and immunotherapy, than a typical liquid biopsy.
Reports Q1 revenue $22.3M, consensus $23.5M. "We are excited about the opportunity to feature GPS Cancer and our new liquid biopsy platform in 11 presentations at next month's American Society of Clinical Oncology Annual Meeting, a significant and auspicious milestone for NantHealth. In conjunction with these presentations, we plan to unveil to the oncology community at ASCO and commence the commercial launch of our liquid biopsy test, a 26 analyte test for circulating-free DNA and RNA extracted from patient blood permits non-invasive detection of expressed biomarkers and monitoring of response to immunotherapies such as Keytruda or Opdivo or resistance to anti-androgens such as Xtandi," said CMO Sandeep Reddy
NantHealth and NantOmics announced joint results that show significant improvements in the accuracy of diagnosis when combining tumor-normal DNA analysis with tumor RNA analysis - as well as the risk for a higher error rate in tumor-only sequencing. The research is included in a paper, "Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer," published last month in the online journal Oncotarget. Dr. Patrick Soon-Shiong, CEO and founder of NantHealth and NantOmics, said the publication showed the significance of combining tumor and normal DNA sequencing in diagnosis - and highlighted the precision of NantOmics' GPS Cancer test. Oncotarget is a multidisciplinary traditional journal focused on making scientific results rapidly and widely available so that exceptional discoveries can be shared quickly. The published results of the NantOmics and NantHealth study show the precision derived from GPS Cancer's comprehensive approach that combines tumor and normal DNA sequencing with RNA sequencing. Highlights from the study include: 95% of genomic variants identified from tumor-only sequencing originated in the germline, therefore, these variants were single nucleotide polymorphisms and false positive tumor somatic variants. After filtering based on population allele frequency to remove SNPs, the false positive rate remained as high as 48%. 29% of lung cancer patients had a false positive variant call in at least one of 12 genes with directly targetable drugs. 18% of true somatic variants identified from tumor and normal DNA sequencing were not expressed in RNA, showing the importance of RNA sequencing to verify gene and variant expression. In a clinical setting, it is important to sequence the tumor and normal DNA as well as the tumor RNA as treatment decisions based on tumor-only sequencing may result in ineffective therapies while also increasing the risk of negative drug-related side effects. GPS Cancer provides a precise and comprehensive molecular profile, integrating tumor-normal sequencing of DNA with RNA sequencing. This approach overcomes the challenges faced by tumor-only DNA sequencing, equipping oncologists with insights that they can rely on to inform their personalized treatment strategies.
Tronc (TRNC) is expected to announced it is selling the Los Angeles Times, the Washington Post reports, citing people familiar with the company's plans. The expected buyer is Patrick Soon-Shiong, an LA-area physician and major stakeholder in Tronc, the report says, citing the people involved in the deal. Soon-Shiong is the founder and CEO of NantHealth (NH) and will also acquire sister newspaper the San Diego Union-Tribune, the report notes. Reference Link